Beta-Amyloid (1-42) Human CAS 107761-42-2

Beta-Amyloid (1-42) human (TB 500) refers to the peptide obtained from the hydrolysis of soybean protein by soybean protease. It is mainly composed of oligopeptides composed of 3~6 amino acids, which can quickly supplement the nitrogen source of human body, recover physical strength and relieve fatigue. Soybean peptides have the functions of low antigenicity, inhibiting cholesterol, promoting lipid metabolism and fermentation. It can be used in food to quickly supplement protein sources, eliminate fatigue and act as a proliferation factor of bifidobacteria. Soybean peptides contain a small amount of macromolecular peptides, free amino acids, sugars and inorganic salts, with a relative molecular weight of less than 1000. The protein content of soybean peptide is about 85%. Its amino acid composition is the same as that of soybean protein. The balance of essential amino acids is good and the content is rich. Compared with soybean protein, soybean peptide has the physiological functions of high digestibility and absorption rate, rapid energy supply, lowering cholesterol, lowering blood pressure and promoting fat metabolism, as well as good processing properties such as no beany smell, no protein denaturation, no acid precipitation, no heating coagulation, easy solubility in water, good fluidity, and is an excellent health food material.

Beta-Amyloid (1-42) human is a pivotal molecule in the development of AD. Its production is intricately linked to the metabolism of Amyloid Precursor Protein (APP), a transmembrane protein that is abundant in neuronal cell membranes and synapses. In healthy individuals, APP undergoes normal metabolic pathways, primarily being cleaved by α-secretase, which produces non-toxic fragments.

However, in AD patients, there is a shift in the metabolic processing of APP. Specifically, there is an increase in the sequential cleavage of APP by β-secretase (BACE1) and γ-secretase. This abnormal cleavage results in the excessive production of Aβ42, which has a higher propensity to aggregate and form amyloid plaques.

The aggregation of Aβ42 into fibrils and oligomers is a critical step in the formation of amyloid plaques, which are a neuropathological hallmark of AD. These plaques disrupt neuronal function, lead to synaptic dysfunction, and ultimately contribute to the cognitive decline and neurodegeneration observed in AD patients.

Thus, targeting the production, aggregation, or clearance of Aβ42 has been a major focus of AD research and therapeutic development. Strategies such as inhibiting BACE1, modulating γ-secretase activity, or enhancing the clearance of Aβ42 through immunotherapy or other mechanisms are being actively pursued to develop effective treatments for AD.

The unique physicochemical properties of Aβ42, particularly its hydrophobicity and propensity to aggregate, make it a key component in the formation of amyloid plaques. These plaques are composed primarily of aggregated Aβ42 fibrils and are a neuropathological hallmark of AD.

The aggregation of Aβ42 into fibrils and oligomers disrupts the structural integrity of neuronal cells, leading to a cascade of complex molecular mechanisms. One of these mechanisms is neuroinflammation, which involves the activation of microglia and astrocytes, the resident immune cells of the brain. These activated immune cells release inflammatory cytokines and chemokines, which can further exacerbate neuronal damage.

Oxidative stress is another critical mechanism in AD pathogenesis. The aggregation of Aβ42 can lead to the production of reactive oxygen species (ROS), which cause oxidative damage to lipids, proteins, and DNA in neuronal cells. This oxidative stress can lead to the disruption of cellular signaling pathways, membrane integrity, and neuronal function.

Finally, the accumulation of amyloid plaques and the associated neuroinflammation and oxidative stress can trigger neuronal apoptosis, or programmed cell death. The loss of neuronal cells, particularly those in the hippocampus and cortex, leads to severe decline in cognitive function, including memory, learning, and executive functions.

Thus, understanding the mechanisms underlying the aggregation of Aβ42 and its neurotoxic effects is crucial for the development of effective therapies to slow or halt the progression of AD. Strategies to inhibit Aβ42 aggregation, enhance its clearance, or target the downstream neurotoxic effects of Aβ42 are being actively pursued in AD research.

Synapses are the sites of communication between neurons, and they play a critical role in the normal physiological activities of the brain. Neurotransmitters are released from the presynaptic terminal and bind to receptors on the postsynaptic membrane, triggering the transmission of signals between neurons.

Beta-Amyloid (1-42) human oligomers have been shown to accumulate at synapses, where they can interact with various synaptic proteins and disrupt the normal function of synapses. For example, Aβ42 oligomers can bind to NMDA receptors, a type of glutamate receptor important for synaptic plasticity and learning, leading to reduced receptor function and impaired synaptic transmission.

In addition, Aβ42 oligomers can also disrupt the trafficking and function of synaptic vesicles, which are responsible for the release of neurotransmitters. This can lead to decreased neurotransmitter release and further impair synaptic transmission.

The accumulation of Aβ42 oligomers at synapses can also lead to changes in synaptic plasticity, a process by which synapses strengthen or weaken in response to neural activity. Impaired synaptic plasticity can affect learning and memory, two cognitive functions that are severely affected in Alzheimer's disease (AD).

Thus, the ability of Aβ42 oligomers to disrupt synaptic function provides another mechanism by which they contribute to the neuropathology of AD. Strategies to target Aβ42 oligomers and their synaptic effects are being actively pursued in AD research as potential therapeutic approaches

In response to the formation of amyloid plaques, microglia, the resident immune cells of the brain, become activated. Activated microglia release inflammatory cytokines and chemokines, which can further exacerbate neuronal damage. This neuroinflammatory response can lead to the recruitment of additional immune cells and the production of additional inflammatory mediators, creating a cycle of inflammation and neuronal damage.

In addition to amyloid plaques, AD is also characterized by the presence of neurofibrillary tangles. These tangles are composed of hyperphosphorylated tau protein, which accumulates inside neurons and disrupts their normal function. The formation of neurofibrillary tangles is closely linked to neuronal degeneration and the loss of neuronal cells.

The activation of microglia and the resulting inflammatory responses can contribute to the formation of neurofibrillary tangles. Inflammatory cytokines and chemokines can affect the phosphorylation and aggregation of tau protein, promoting the formation of tangles. Additionally, activated microglia can phagocytose and degrade neurons, further contributing to neuronal loss.

Thus, the formation of amyloid plaques, the activation of microglia, and the resulting inflammatory responses are all critical components of the neuropathological cascade that leads to AD. Understanding the mechanisms underlying these processes is crucial for the development of effective therapies to slow or halt the progression of AD.

• Enzyme-Linked Immunosorbent Assay (ELISA) is a commonly used method for measuring Aβ42 levels in biological samples such as cerebrospinal fluid (CSF) and plasma. ELISA is a highly sensitive and specific technique that uses antibodies to bind and detect specific proteins, such as Aβ42. By measuring the amount of antibody-bound Aβ42, researchers can quantify the levels of Aβ42 in a sample.
• Immunohistochemistry (IHC) is another method that can be used to detect and quantify Aβ42 in brain tissue. IHC involves the use of antibodies to stain specific proteins in tissue sections, allowing researchers to visualize and quantify the distribution and abundance of Aβ42 in the brain. IHC can be particularly useful for studying the neuropathological changes that occur in AD, such as the formation of amyloid plaques.

Immunotherapy, particularly Aβ vaccines, has been a focal point of AD research for many years. These vaccines stimulate the immune system to produce antibodies against Aβ42, which can then bind and clear amyloid plaques from the brain. However, despite promising results in animal studies, clinical trials of Aβ vaccines in humans have faced challenges, including immune responses against the vaccine itself and the development of anti-drug antibodies.

Small molecule inhibitors, such as BACE1 inhibitors, target the beta-secretase enzyme that cleaves the amyloid precursor protein (APP) to produce Aβ42. By inhibiting BACE1, these drugs can reduce the production of Aβ42 and slow the progression of AD. However, BACE1 is also involved in the processing of other proteins, so these drugs may have off-target effects that limit their use.

Gene therapy is another promising approach for targeting Aβ42 in AD. By delivering genes encoding enzymes or other proteins that promote the clearance or degradation of Aβ42, gene therapy could potentially reduce amyloid plaque formation and slow the progression of AD. However, gene therapy is still in its early stages of development, and there are many technical and ethical challenges that need to be addressed before it can be widely used in clinical practice.

Beta-Amyloid (1-42) human, also known as Aβ(1-42) or amyloid beta-peptide (1-42), is a key peptide fragment implicated in the pathogenesis of Alzheimer's disease (AD). It is a product of proteolytic cleavage of the amyloid precursor protein (APP), a transmembrane glycoprotein widely expressed in neurons and other cell types.This specific peptide consists of 42 amino acids, derived from the sequential cleavage of APP by β-secretase (BACE1) and γ-secretase.

Unlike its shorter counterpart, Aβ(1-40), Aβ(1-42) is more hydrophobic and prone to aggregation, forming oligomers, fibrils, and eventually amyloid plaques in the brain. These plaques are a hallmark of AD, contributing to neuronal dysfunction and death.

The aggregation process of Aβ(1-42) is complex, involving various conformational changes and interactions with other biomolecules. These aggregates are believed to disrupt synaptic function, induce oxidative stress, and promote inflammation, leading to cognitive decline and memory loss.

Research into Aβ(1-42)'s role in AD has intensified efforts to develop therapeutic strategies targeting its production, aggregation, or clearance. These include β- and γ-secretase inhibitors, immunotherapies aimed at reducing plaque load, and molecules that stabilize or disrupt specific oligomeric states of Aβ(1-42). Understanding the mechanisms underlying Aβ(1-42) toxicity and aggregation remains crucial for advancing treatments and ultimately finding a cure for Alzheimer's disease.

It is a paradoxical molecule: a driver of neurodegeneration in its aggregated form and a guardian of neuronal health in its monomeric state. Advances in cryo-EM, biomarker development, and immunotherapy have transformed our understanding of Aβ42's roles in AD, yet challenges remain in translating preclinical findings into effective treatments. Future research must reconcile Aβ42's duality, leverage structural insights for drug design, and integrate personalized approaches to combat this devastating disease.

Hot Tags: beta-amyloid (1-42) human cas 107761-42-2, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, DERMORPHIN, Cosmetic, Melanotan ii powder, dermorphin peptide, dermorphin in humans